drugset
drugset / Trial / NCT03890185

Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC

NCT03890185 ↗

Phase 2 Unknown 108 enrolled King Faisal Specialist Hospital & Research Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The central hypothesis is to test Low Dose Fraction Radiotherapy (LDFRT), as a potentiator of Docetaxel and Cisplatin efficacy in locally advanced nasopharyngeal cancer.

Timeline

Start
2012-10-01
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous

Indications

nasopharyngeal carcinoma